Outcomes Research

 
Stock Quotes for Outcomes Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
Sign-up for cot investment picks

 
News Articles for Outcomes Research top ^
2014/7/8
A new cancer care payment model that rewards physicians for focusing on best treatment practices and health outcomes rather than the number of drugs they prescribe resulted in significant cost savings without affecting the quality of care.
Sign-up for Study: New Cancer Care Payment Model Reduced Health Care Costs, Maintained Outcomes investment picks
Ninety-two percent of executives from companies that are applying big data to their businesses said they are satisfied with the results, according to new research by Accenture (NYSE: ACN). Eighty-nine percent of respondents rated big data as “very important” or “extremely important” to their businesses’ digital transformation, and 82 percent agreed big data provides a significant source of value for their companies.
Sign-up for Companies Are Satisfied with Business Outcomes from Big Data and Recognize Big Data as Very Important to Their Digital Transformation, Accenture Study Shows investment picks
Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc. (Nasdaq: ACOR ) and HealthCore Inc. at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
Sign-up for Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA investment picks
PARIS and MINNEAPOLIS, June 14, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) and Medtronic, Inc. (NYSE:MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world.
Sign-up for Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes investment picks
ATLANTA , June 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries.
Sign-up for Alimera Sciences' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G017800-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/7/2/11G017800/Medtronic-525806306920.jpg BRAMPTON, ON--(Marketwired - July 02, 2014) - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE: MDT) today announced the results of the global OpT2mise trial, which included eight participating centres in Canada.
Sign-up for People With Type 2 Diabetes Achieve Superior Outcomes With Insulin Pumps vs. Multiple Daily Injections investment picks
2014/8/26
Highest level evidence published in Neurosurgery journal indicates better outcomes when using iMRI Canada NewsWire Interim analysis of triple-blind, parallel-controlled trial proves intraoperative MRI more effective than conventional neurosurgery for certain brain tumors MINNEAPOLIS , Aug.
Sign-up for Highest level evidence published in Neurosurgery journal indicates better outcomes when using iMRI investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMB r I sentan and T adalafil in patients with pulmonary arterial hypertens ION ), which was conducted in collaboration with GlaxoSmithKline (GSK). In AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint (p<0.01). Rates of serious adverse events and events leading to discontinuation were similar across treatment arms.
Sign-up for First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study investment picks
http://media.marketwire.com/attachments/201402/227789_CBLI_logo2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1141504&ProfileId=051205&sourceType=1 BUFFALO, NY --
Sign-up for Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0954338001&sourceType=1 TORONTO, ONTARIO --
Sign-up for United Corporations Limited Announces Outcome of Director Elections investment picks
2014/6/19
http://media.marketwire.com/attachments/201308/176350_IMPrtnrSmrt_RandTM_032812.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1125277&ProfileId=051205&sourceType=1 SANTA ANA, CA --
Sign-up for Ingram Micro Adds Pearson's K-12 Ed-Tech Solutions to Its Portfolio to Improve Student Outcomes investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 144 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After nearly three years of follow up, results on the 6-minute walk test (6MWT) showed a decline in walking ability at a rate slower than would be expected based on available DMD natural history data.
Sign-up for Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy investment picks
2014/7/21
Montefiore Medical Center is collaborating with UnitedHealthcare to provide enhanced, coordinated care to more than 9,000 New York residents enrolled in UnitedHealthcare’s employer-sponsored health plans, including Oxford Health-branded plans.
Sign-up for Montefiore Medical Center and UnitedHealthcare Collaborate to Enhance Care, Improve Outcomes and Reduce Costs investment picks
2014/8/26
Interim analysis of triple-blind, parallel-controlled trial proves intraoperative MRI more effective than conventional neurosurgery for certain brain tumors MINNEAPOLIS , Aug.
Sign-up for Highest level evidence published in Neurosurgery journal indicates better outcomes when using iMRI investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Outcomes Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Ounces Gold  |  Next: Outside Companies